August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology

The first-line immunotherapy combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) continues to show robust, durable clinical benefit, with a deepening of response, in patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), according to results presented at the ASCO 2020 virtual annual meeting.
Read More

There is a new standard of care in the first-line treatment setting for the subset of patients with advanced colorectal cancer (CRC) that is associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), according to data presented at the ASCO 2020 virtual annual meeting.
Read More

Cellular therapy is becoming an attractive option for heavily pretreated patients with relapsed or refractory multiple myeloma.
Read More

Pembrolizumab (Keytruda) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with metasstatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
Read More

Early locoregional therapy with surgery and radiation does not improve overall survival (OS) in women with newly diagnosed stage IV breast cancer and an intact primary tumor compared with systemic therapy alone, according to the results of the randomized ECOG-ACRIN E2108 phase 3 clinical trial.
Read More

When ASCO President Howard A. Burris III, MD, FACP, FASCO, chose the theme for the 2020 annual meeting—“Unite and Conquer: Accelerating Progress Together”—early last year, he never imagined that it would take on new meaning just 12 months later.
Read More

  • Inqovi First Oral Hypomethylating Agent Approved for Intermediate- or High-Risk Myelodysplastic Syndromes
  • Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
  • Opdivo Now Approved for Advanced Esophageal Squamous-Cell Carcinoma
  • Cyramza plus Tarceva Approved for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
  • Tecentriq plus Avastin Combination Approved for First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma
  • Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More

With follow-up of more than 5 years, women with relapsed platinum-sensitive ovarian cancer and a BRCA mutation who participated in the multicenter phase 3 SOLO2 clinical trial lived more than 1 year longer when randomized to maintenance therapy with the poly (ADP- ribose) polymerase (PARP) inhibitor olaparib (Lynparza) compared with placebo, according to data released at the ASCO 2020 virtual annual meeting.
Read More

The small-molecule inhibitor of tyrosine kinase WEE1 adavosertib demonstrated promising clinical activity in a single-arm, phase 2 study of patients with unselected uterine serous cancer (USC), with an objective response rate of 29.4%, said Joyce F. Liu, MD, MPH, Director of Clinical Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting.
Read More

A novel intratumoral chemotherapy agent delivered by direct injection permits the dispersion of cytotoxic drugs into cancer cells to eradicate tumors. Data from a phase 1/2 trial of intratumoral INT230-6, alone and in combination with pembrolizumab (Keytruda), in patients with advanced solid tumors was presented at the ASCO 2020 virtual annual meeting.
Read More

Page 2 of 3